Author

Xiaomei Liao 1

1 AbbVie,North Chicago,United States

52-WEEKS RISANKIZUMAB SUBCUTANEOUS MAINTENANCE DOSING IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO HAD DELAYED RESPONSE TO 12-WEEKS IV RISANKIZUMAB INDUCTION

Geert R. D'Haens, Remo Panaccione, Julian Panés, Tadakazu Hisamatsu, Peter Bossuyt, Silvio Danese, Ezequiel Neimark, Alexandra Song, Xiaomei Liao, Kori Wallace, Javier Zambrano, Rachel Duan, Kristina Kligys, Marla C. Dubinsky

AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES

Geert R. D'Haens, Brian Feagan, William J. Sandborn, Remo Panaccione, Julian Panés, Tadakazu Hisamatsu, Marc Ferrante, Ezequiel Neimark, Peter Bossuyt, Silvio Danese, Alexandra Song, Xiaomei Liao, Tian Feng, Rachel Duan, Sofie Berg, Jean-Frédéric Colombel, Kori Wallace

Early symptom improvement with risankizumab treatment in patients with moderately to severely active Crohn's disease: analysis from a Phase 2 study

Brian G. Feagan, William Sandborn, Geert R. D'Haens, Julian Panés, Arthur Kaser, Marc Ferrante, Edouard Louis, Olivier Dewit, Ursula Seidler, Kyung-Jo Kim, Kristina Kligys, Kori Wallace, Xiaomei Liao, Wan-Ju Lee, Markus F. Neurath

EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN'S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY

Marc Ferrante, Xiaomei Liao, Yinuo Pang, Valerie Pivorunas, Tadakazu Hisamatsu

Long-term safety and efficacy of risankizumab treatment in patients with Crohn's disease: 3-year interim results from the ongoing Phase 2 open-label extension study

Marc Ferrante, Brian G. Feagan, Julian Panés, Filip Baert, Edouard Louis, Olivier Dewit, Arthur Kaser, Weijiang Rachel Duan, Dawn Gustafson, Xiaomei Liao, Kori Wallace, Jasmina Kalabic, Geert R. D'Haens

LONG-TERM SAFETY AND EFFICACY OF RISANKIZUMAB TREATMENT IN PATIENTS WITH CROHN'S DISEASE: INTERIM RESULTS OF THE ONGOING PHASE 2 OPEN-LABEL EXTENSION STUDY

Marc Ferrante, Julian Panés, Filip Baert, Edouard Louis, Arthur Kaser, Dawn Gustafson, David Hall, Wulf O. Böcher, Ivona Herichova, Xiaomei Liao, Kori Wallace, Jasmina Kalabic, Geert R. D'Haens

RISANKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE WHO FAILED 1 VS > 1 PRIOR BIOLOGIC TREATMENT: RESULTS FROM THE MOTIVATE STUDY

Remo Panaccione, Stefan Schreiber, Laurent Peyrin-Biroulet, Edward V. Loftus, Marla C. Dubinsky, Marc Ferrante, Alexandra Song, Bidan Huang, Xiaomei Liao, Sofie Berg, Rachel Duan, Kori Wallace, Brian Feagan

Item 1 - 7 / 7
1